Highbridge Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Highbridge Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-60,746	Closed	-$128K	–	2219
2017 Q3	$128K	Buy	60,746 +15,426	+34%	+$37.6K	﹤0.01%	1462
2017 Q2	$132K	Buy	+45,320	New	+$136K	﹤0.01%	1163
2015 Q3	–	Sell	-6,247	Closed	-$214K	–	2072
2015 Q2	$309K	Buy	6,247 +618	+11%	+$36.9K	﹤0.01%	1136
2015 Q1	$441K	Buy	+5,629	New	+$349K	0.01%	1002
2014 Q4	–	Sell	-48,963	Closed	-$2.09M	–	1685
2014 Q3	$2.09M	Buy	+48,963	New	+$2.63M	0.03%	473
2013 Q4	–	Sell	-2,954	Closed	-$181K	–	1609
2013 Q3	$181K	Buy	+2,954	New	+$200K	﹤0.01%	1183

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Highbridge Capital Management's OREX Position: Q4 2017 in Review

Highbridge Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 60,746 shares — an estimated $128K sold.

Highbridge Capital Management first reported a position in OREX in Q3 2013 and held it in 6 quarters. The position peaked at $2.09M in Q3 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

Highbridge Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Highbridge Capital Management sold 60,746 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $128K.
Highbridge Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 6 quarters.
Highbridge Capital Management's Orexigen Therapeutics, Inc. position peaked at $2.09M in Q3 2014.
41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.